Conditions

Prostate Cancer

Prostatic Neoplasms

Purpose of the study

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy. NCT06925737    

Official Title

Ph3 Trial of MK-2400 (ifinatamab deruxtecan) versus Physician’s Choice of docetaxel or alternative ARPI in Pre-chemotherapy Metastatic Castration-Resistant Prostate Cancer (IDeate-Prostate01) 

Who is eligible to participate?

Inclusion criteria

• Participants must have diagnosis of metastatic castration-resistant prostate cancer (mCRPC)

• Participants must have prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to entering the study

• Participants must have received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after at least 8 weeks of treatment

Exclusion Criteria:

• Participants must not have any gastrointestinal disorder that affects absorption

• Participants must not have history of non-infectious ILD/Pneumonitis

• Participants must not have clinically severe pulmonary compromise

Register your interest

To register your interest or find out more information about this clinical trial, please email: enquiries@gallipoliresearch.org.au. 

Study location

Gallipoli Medical Research, Greenslopes Private Hospital, Brisbane